• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-08-14

  A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct, degradation-sensitive target of the cardiotonic steroid Bufalin in triple-negative breast cancer. By combining chemical-proteomic target discovery, biophysical binding assays, genetic perturbation, animal models, and patient-derived organoids, the work connects Bufalin–STK33 engagement to disruption of an STK33–HSP90 stability mechanism and suppression of tumor growth.

• TMJ Inflammation, Microglia, and Synaptic Pruning

  2026-08-14

  This study identifies a mechanistic pathway linking temporomandibular joint inflammation to hippocampal microglial activation, neuronal C3 deposition, excessive synaptic pruning, and depression-like behaviors in mice. Its perturbation-based design highlights microglial Nr4a1 and neuronal C3 as experimentally testable nodes while clarifying the limits of translating these findings to other inflammatory signaling models.

• In Vitro Cancer Drug Response: Growth vs Death

  2026-08-13

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability when measuring anticancer drug responses in vitro. The framework shows that growth inhibition and cell death are related but non-equivalent outcomes, supporting more informative assay design and interpretation.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-08-13

  Grafton et al. developed a scalable high-content screening strategy that combines human iPSC-derived cardiomyocytes with deep-learning image analysis to identify drug-induced cardiotoxic phenotypes. Screening both annotated bioactive compounds and molecules with unknown targets showed that a single image-derived score can support early liability detection and chemical prioritization.

• Tetrahedral DNA Frameworks Improve Enzymatic DNA Synthesis

  2026-08-12

  The reference study engineers a tetrahedral DNA nanostructure interface that presents primers in a more ordered geometry for terminal-transferase-based oligonucleotide synthesis. Its results associate this architecture with improved enzyme accessibility, fewer deletion errors, and a practical DNA information-storage demonstration.

• Phytol: RXR Assays and the Architecture of Evidence

  2026-08-12

  Phytol supports a rigorous strategy for separating RXR activation from metabolic and GABAergic effects. This guide combines receptor pharmacology with lessons from polymer self-assembly to improve assay design, controls, and interpretation.

• Doxycycline Workflows for MMP2 Cancer Research

  2026-08-11

  Build reproducible Doxycycline experiments around antimicrobial activity, antiproliferative effects, and metalloproteinase inhibition. This workflow also shows how to use Doxycycline as a mechanistic control when evaluating MMP2-responsive peptide nanocarriers without confusing enzyme inhibition with targeted drug delivery.

• CPI-613 Workflows for Tumor Metabolism

  2026-08-11

  CPI-613 enables linked measurements of mitochondrial dysfunction, apoptosis, and tumor–immune metabolic signaling rather than relying on viability alone. This workflow-focused guide translates recent PDHA1 succinylation findings into practical assays for cholangiocarcinoma, acute myeloid leukemia research, and non-small cell lung carcinoma research.

• Busulfan Workflows for Senescence and Germ Cell Models

  2026-08-10

  Busulfan enables complementary experimental models: dose-controlled senescence induction in WI38 fibroblasts and chemically induced germ-cell depletion for ovarian lineage-tracing studies. This practical guide connects DNA crosslinking, MAPK readouts, dual-recombinase controls, formulation, and troubleshooting for more reproducible bench workflows.

• APEX2, TERT Expression, and Stem Cell DNA Repair

  2026-08-09

  This preprint identifies APEX2 as a previously unrecognized regulator of efficient TERT expression and telomerase activity in human embryonic stem cells. Its combination of knockdown, RNA-seq, and chromatin immunoprecipitation links repetitive DNA elements, particularly MIR sequences, to transcriptional control, while also highlighting important limitations for mechanistic and therapeutic interpretation.

• WM-8014 in Reproducible Cell Assays

  2026-08-08

  WM-8014 (SKU A8779) is a reversible, competitive KAT6A/B inhibitor for separating cell-cycle arrest and senescence from nonspecific cytotoxicity in cancer biology research. This scenario-based guide covers assay design, formulation limits, data interpretation, and practical supplier-selection criteria.

• (S)-(+)-Methoprene: Juvenile Hormone Pathways

  2026-08-07

  (S)-(+)-Methoprene is a juvenile hormone analog used to interrogate Met-dependent developmental signaling in arthropods. Its strongest research value is mechanistic: it links receptor activation and insect metamorphosis inhibition with experimental studies of hormone-regulated development, transcriptional control, and endocrine disruption.

• (S)-(+)-Methoprene: A Benchmark Juvenile Hormone Analog

  2026-08-07

  (S)-(+)-Methoprene is a potent and selective juvenile hormone analog used as a tool compound in studies of insect development and endocrine disruption. Its high-affinity activation of the Methoprene-tolerant receptor inhibits metamorphosis and maintains larval states, with broad utility in research on hormone-regulated processes. The compound’s low mammalian toxicity supports its role in comparative toxicology and receptor signaling investigations.

• Ferrostatin-1 (Fer-1): Redefining Ferroptosis in Translation

  2026-08-06

  Discover how Ferrostatin-1 (Fer-1) is empowering translational researchers to mechanistically dissect and strategically target ferroptosis in cancer and neurodegenerative disease models. This article integrates new evidence from bladder cancer studies and offers protocol guidance, workflow optimization, and clinical perspectives that surpass conventional product narratives.

• SCH772984 HCl: Advanced ERK1/2 Inhibition in Stem Cell and C

  2026-08-06

  Discover how SCH772984 HCl, a potent ERK1/2 inhibitor, uniquely bridges stem cell biology and BRAF/RAS-mutant cancer research. Explore mechanistic insights, protocol guidance, and the latest evidence linking MAPK pathway targeting to telomerase regulation.

17050 records 1/1137 page Next 12345 下5页 Last page